|Bid||23.55 x 800|
|Ask||23.53 x 2900|
|Day's Range||23.50 - 24.31|
|52 Week Range||11.05 - 24.84|
|Beta (3Y Monthly)||0.62|
|PE Ratio (TTM)||373.33|
|Earnings Date||Jul 30, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||24.00|
MYERS, FL / ACCESSWIRE / July 9, 2019 / NeoGenomics, Inc. (NEO), a leading provider of cancer-focused genetic testing services, today announced that it intends to build a leading-edge cancer diagnostics testing facility and new global business headquarters in Fort Myers, Florida. Importantly, the site is a short drive from the existing NeoGenomics footprint in Fort Myers and remains in the vicinity of the Southwest Florida International Airport. The Florida Department of Economic Opportunity (“DEO”) and Lee County have agreed to support NeoGenomics’ expansion to encourage the company’s growth of high-paying jobs in a “high-impact sector” of the local economy.
FT MYERS, FL / ACCESSWIRE / July 1, 2019 / NeoGenomics, Inc. (NASDAQ: NEO) , a leading provider of cancer-focused genetic testing services, announced today that it plans to release its second quarter 2019 ...
FORT MYERS, FL / ACCESSWIRE / June 27, 2019 / NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today announced that the company has entered into a new $250 ...
We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, smart money investors have to conduct complex analyses, spend many resources and use tools that are not always […]
Neogenomics Inc NASDAQ:NEOView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is moderate for NEO with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding NEO are favorable, with net inflows of $1.27 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
FT. MYERS, FL / ACCESSWIRE / May 30, 2019 / NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today announced that Doug VanOort, Chairman and Chief Executive ...
FT. MYERS, FL / ACCESSWIRE / May 28, 2019 / NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today announced availability of the QIAGEN therascreen® PIK3CA ...
FT. MYERS, FL / ACCESWIRE / May 23, 2019 / NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today announced that Doug VanOort, Chief Executive Officer, Sharon ...
MYERS, FL / ACCESSWIRE / May 21, 2019 / NeoGenomics, Inc. (NEO), a leading provider of cancer-focused genetic testing services, today announced the pricing of its underwritten public offering of 7,000,000 shares of its common stock at a public offering price of $21.25 per share. Gross proceeds to NeoGenomics from the offering, before deducting the underwriting discounts and commissions and estimated offering expenses payable by NeoGenomics, are expected to be $148,750,000. All shares of common stock to be sold in the offering are being sold by NeoGenomics.
Stock futures signaled solid market gains as the U.S. eased Huawei curbs. On Monday those curbs triggered a big sell-off in chip stocks like Broadcom and sent the Nasdaq tumbling.
MYERS, FL / ACCESSWIRE / May 20, 2019 / NeoGenomics, Inc. (NEO), a leading provider of cancer-focused genetic testing services, announced today that it has commenced an underwritten public offering of approximately $150,000,000 of newly issued shares of common stock. All shares of common stock to be sold in the offering are being sold by NeoGenomics. In addition, NeoGenomics expects to grant the underwriters a 30-day option to purchase up to an additional $22,500,000 of shares of common stock at the public offering price, less underwriting discounts and commissions.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! NeoGenomics, Inc. (NASDAQ:NEO) is a small-cap stock with a market capitalization of US$2.2b. While in...
NeoGenomics (NEO) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Hedge funds run by legendary names like George Soros and David Tepper make billions of dollars a year for themselves and their super-rich accredited investors (you’ve got to have a minimum of $1 million liquid to invest in a hedge fund) by spending enormous resources on analyzing and uncovering data about small-cap stocks that the […]
NeoGenomics (NEO) delivered earnings and revenue surprises of 40.00% and 9.13%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
The Fort Myers, Florida-based company said it had a loss of 3 cents per share. Earnings, adjusted for non-recurring costs and amortization costs, came to 7 cents per share. The results exceeded Wall Street ...
FT. MYERS, F L / ACCESSWIRE / April 30, 2019 / NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today reported its results for the first quarter of 2019. ...
NeoGenomics (NEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.